Sanjivani Paranteral Limited (SANJIVIN) Fair Value & Analysis
Healthcare · IN · Market cap ₹1.9B
Fair value as of: Jul 6, 2026
From 14 valuation models · updated today
Share price +7.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹129.30 – ₹253.47 · fair‑value band ₹77.51 – ₹136.25 · the ₹154.95 price screens above the ₹106.88 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sanjivani Paranteral Limited (SANJIVIN) currently trades at ₹154.95, while our model-based Fair Value estimate is ₹106.88 — implying the stock looks roughly 31.0% overvalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Sanjivani Paranteral Limited generated revenue of ₹687M at a net margin of 9.9%. Revenue declined 27.3% year over year. It earns a return on equity of 14.8%. Net debt stands at ₹130M. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹77.51 (bear case) to ₹136.25 (bull case); at ₹154.95, the current price sits above that range. The share trades about 42% below its 52-week high and 23% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside — at -31%, SANJIVIN screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Sanjivani Paranteral Limited operates as a pharmaceutical company in India. It manufactures pharmaceutical products in a form of oral solids, small volume parenteral, and sterile powder formulations for various therapeutic areas comprising central nervous system, cardiovascular system, antibiotics, gastroenterological, anti-diabetics, and anti-allergic. It also offers soft gels, topicals, nasal sprays, liquid injection, capsules, tablets, dry syrups, and ear/eye drops. The company also exports its products. Sanjivani Paranteral Limited was incorporated in 1994 and is headquartered in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sanjivani Paranteral Limited reported revenue of ₹687M in FY2026 versus ₹304M in FY2022, a compound +22.6%/yr. Reported net income was ₹66.9M in FY2026, compounding +8.4%/yr from FY2022.
Is SANJIVIN fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sanjivani Paranteral Limited (SANJIVIN) undervalued?
What is the fair value of SANJIVIN?
What is the quality score of SANJIVIN?
What is the revenue of Sanjivani Paranteral Limited (SANJIVIN)?
What is the net profit margin of SANJIVIN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.